Silibinin Suppresses Growth of Human Colorectal Carcinoma SW480 Cells in Culture and Xenograft through Down-regulation of β-Catenin-Dependent Signaling
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Mutations in APC/beta-catenin resulting in an aberrant activation of Wnt/beta-catenin pathway are common in colorectal cancer (CRC), suggesting that targeting the beta-catenin pathway with chemopreventive/anticancer agents could be a potential translational approach to control CRC. Using human CRC cell lines harboring mutant (SW480) versus wildtype (HCT116) APC gene and alteration in beta-catenin pathway, herein we performed both in vitro and in vivo studies to examine for the first time whether silibinin targets beta-catenin pathway in its efficacy against CRC. Silibinin treatment inhibited cell growth, induced cell death, and decreased nuclear and cytoplasmic levels of beta-catenin in SW480 but not in HCT116 cells, suggesting its selective effect on the beta-catenin pathway and associated biologic responses. Other studies, therefore, were performed only in SW480 cells where silibinin significantly decreased beta-catenin-dependent T-cell factor-4 (TCF-4) transcriptional activity and protein expression of beta-catenin target genes such as c-Myc and cyclin D1. Silibinin also decreased cyclin-dependent kinase 8 (CDK8), a CRC oncoprotein that positively regulates beta-catenin activity, and cyclin C expression. In a SW480 tumor xenograft study, 100- and 200-mg/kg doses of silibinin feeding for 6 weeks inhibited tumor growth by 26% to 46% (P < .001). Analyses of xenografts showed that similar to cell culture findings, silibinin decreases proliferation and expression of beta-catenin, cyclin D1, c-Myc, and CDK8 but induces apoptosis in vivo. Together, these findings suggest that silibinin inhibits the growth of SW480 tumors carrying the mutant APC gene by down-regulating CDK8 and beta-catenin signaling and, therefore, could be an effective agent against CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524 · cited 1×
“To address the issue of dose translation from one species to another, calculation of human equivalent dose (HED) using normalization of the body surface area instead of weight has been advocated [48].”
BackgroundCancer chemoprevention with dietary phytochemicals
Surh, Y.-J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1189 · Cited by 2,955 · cited 1×
“To date, many food/ plant–derived chemopreventive agents that exhibit strong efficacy against various cancers in in vitro and preclinical models have been identified [11–14].”
BackgroundWNT and β-catenin signalling: diseases and therapies
Moon, R. T., Kohn, A. D., Ferrari, G. V. D., & Kaykas, A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1427 · Cited by 1,763 · cited 1×
“Aberrant Wnt signaling has been reported to contribute to various human diseases including CRC [23].”
Backgroundβ-Catenin destruction complex: insights and questions from a structural perspective
Kimelman, D., & Xu, W. (2006) · Oncogene · doi:10.1038/sj.onc.1210055 · Cited by 628 · cited 1×
“The first canonical pathway involves multiprotein destruction complex, consisting of GSK-3β, casein kinase 1, APC, and axin, which targets β-catenin for proteasomal degradation [36]; the second pathway involves p53/Siah1 [37]; and the third pathway involves nuclear hormone receptor–mediated degradation of β-catenin [3…”
BackgroundThe APC gene in colorectal cancer
Fodde, R. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00040-0 · Cited by 461 · cited 1×
“Germ line mutations in the APC gene are seen in patients whose conditions have been diagnosed as familial adenomatous polyposis or CRC [27].”
Background
Cited by
Wnt signaling in colorectal cancer: Pathogenic role and therapeutic target
Zhao, H., Ming, T., Tang, S., Ren, S., Yang, H., Liu, M., Tao, Q., & Xu, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01616-7 · Cited by 857
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer
Deep, G., & Agarwal, R. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9237-0 · Cited by 253
Self-citationFlavonoids: Potential Wnt/beta-catenin signaling modulators in cancer
Amado, N. G., Fonseca, B. F., Cerqueira, D. M., Neto, V. M., & Abreu, J. G. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.05.003 · Cited by 125
“However, in HCT116 cells (colorectal cancer wild type for Wnt signals), Silibinin have no effect, suggesting its selective effects on the Wnt/β-catenin pathway (Kaur et al., 2010).”
BackgroundIron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications
Rao, V. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4877 · Cited by 37
Metadata
- Authors
- Kaur, M., Velmurugan, B., Tyagi, A., Agarwal, C., Singh, R. P., & Agarwal, R.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 12
- Issue
- 5
- Pages
- 415-424
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W1489084607
- Cited by
- 110
- References
- 6
- FWCI
- 8.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.